دورية أكاديمية
أعرض في EDS

Clinical and biomarker assessment of frailty in liver transplantation.

التفاصيل البيبلوغرافية
العنوان: Clinical and biomarker assessment of frailty in liver transplantation.
المؤلفون: Ayorinde T; Division of Transplant and Hepatobiliary Surgery, Department of Surgery., Panayotova G; Division of Transplant and Hepatobiliary Surgery, Department of Surgery., Sharma A; Division of Transplant and Hepatobiliary Surgery, Department of Surgery., Lunsford KE; Division of Transplant and Hepatobiliary Surgery, Department of Surgery.; Center for Immunity and Inflammation, Institute for Infectious and Inflammatory Diseases, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
المصدر: Current opinion in organ transplantation [Curr Opin Organ Transplant] 2021 Oct 01; Vol. 26 (5), pp. 488-497.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9717388 Publication Model: Print Cited Medium: Internet ISSN: 1531-7013 (Electronic) Linking ISSN: 10872418 NLM ISO Abbreviation: Curr Opin Organ Transplant Subsets: MEDLINE
أسماء مطبوعة: Publication: <2003->: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Philadelphia, PA : Rapid Science Publishers,
مواضيع طبية MeSH: Frailty*/diagnosis , Liver Transplantation* , Sarcopenia*/diagnosis, Biomarkers ; Humans ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/surgery
مستخلص: Purpose of Review: Liver cirrhosis results in progressive decline, or frailty, which leads to poor outcomes and decreased survival. Multiple biomarkers and clinical assessment tools for quantifying frailty in liver transplant candidates exist, but a universal scoring protocol is lacking. Criteria vary between studies and correlation with patient outcome is not always clear. This review aims to summarize the pertinent biomarkers and assessment tools of frailty in cirrhosis.
Recent Findings: As cirrhosis progresses, the resultant 'frailty' is an inseparable independent predictor of pre and posttransplant mortality. Pro-inflammatory, neuroendocrine, and adipokine factors are dysregulated - leading to paradoxical anorexia and downregulation of orexigenic signals. The resulting catabolic utilization of amino and fatty acids leads to progressive malnutrition and sarcopenia. Both functional and imaging criteria define sarcopenia in cirrhotic patients, and degree of debilitation correlates with mortality. Liver-disease-specific frailty biomarkers and scoring tools are optimal to assess physical dysfunction in cirrhotics to promote early diagnosis and intervention.
Summary: Liver cirrhosis and resulting frailty are progressive and portend a poor patient prognosis. A comprehensive, validated algorithm for detecting and quantifying frailty specific to liver disease would allow for standardization and facile application in the clinical setting. Early diagnosis is key for timely intervention and improved patient outcomes.
(Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
References: Haugen CE, McAdams-DeMarco M, Holscher CM, et al. Multicenter study of age, frailty, and waitlist mortality among liver transplant candidates. Ann Surg 2020; 271:1132–1136.
Van Jacobs AC. Frailty assessment in patients with liver cirrhosis. Clin Liver Dis 2019; 14:121–125.
Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91–96.
Montano-Loza AJ. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol 2014; 20:8061–8071.
Purnak T, Yilmaz Y. Liver disease and malnutrition. Best Pract Res Clin Gastroenterol 2013; 27:619–629.
Lai JC, Volk ML, Strasburg D, Alexander N. Performance-based measures associate with frailty in patients with end-stage liver disease. Transplantation 2016; 100:2656–2660.
Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66:564–574.
Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17:445–450.
Izumi T, Watanabe J, Tohyama T, Takada Y. Impact of psoas muscle index on short-term outcome after living donor liver transplantation. Turk J Gastroenterol 2016; 27:382–388.
Sundaram V, Lim J, Tholey DM, et al. The Braden Scale, a standard tool for assessing pressure ulcer risk, predicts early outcomes after liver transplantation. Liver Transpl 2017; 23:1153–1160.
Guaraldi G, Dolci G, Zona S, et al. A frailty index predicts postliver transplant morbidity and mortality in HIV-positive patients. AIDS Res Ther 2017; 14:37.
Dolgin NH, Martins PN, Movahedi B, et al. Functional status predicts postoperative mortality after liver transplantation. Clin Transplant 2016; 30:1403–1410.
Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and consequences of innate immune dysfunction in cirrhosis. Front Immunol 2019; 10:293.
Dirchwolf M, Podhorzer A, Marino M, et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. Cytokine 2016; 77:14–25.
Noor MT, Manoria P. Immune dysfunction in cirrhosis. J Clin Transl Hepatol 2017; 5:50–58.
Wang CW, Feng S, Covinsky KE, et al. A comparison of muscle function, mass, and quality in liver transplant candidates: results from the functional assessment in liver transplantation study. Transplantation 2016; 100:1692–1698.
Mysore KR, Ghobrial RM, Kannanganat S, et al. Longitudinal assessment of T cell inhibitory receptors in liver transplant recipients and their association with posttransplant infections. Am J Transplant 2018; 18:351–363.
Dolz C, Raurich JM, Ibanez J, et al. Ascites increases the resting energy expenditure in liver cirrhosis. Gastroenterology 1991; 100:738–744.
Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016; 65:1232–1244.
Kakazu E, Kondo Y, Kogure T, et al. Plasma amino acids imbalance in cirrhotic patients disturbs the tricarboxylic acid cycle of dendritic cell. Sci Rep 2013; 3:3459.
Buchard B, Boirie Y, Cassagnes L, et al. Assessment of malnutrition, sarcopenia and frailty in patients with cirrhosis: which tools should we use in clinical practice? Nutrients 2020; 12:186.
Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017; 36:49–64.
Laube R, Wang H, Park L, et al. Frailty in advanced liver disease. Liver Int 2018; 38:2117–2128.
Georgiou A, Papatheodoridis GV, Alexopoulou A, et al. Evaluation of the effectiveness of eight screening tools in detecting risk of malnutrition in cirrhotic patients: the KIRRHOS study. Br J Nutr 2019; 122:1368–1376.
Lim HS, Kim HC, Park YH, Kim SK. Evaluation of malnutrition risk after liver transplantation using the nutritional screening tools. Clin Nutr Res 2015; 4:242–249.
Chapman B, Sinclair M, Gow PJ, Testro AG. Malnutrition in cirrhosis: more food for thought. World J Hepatol 2020; 12:883–896.
Evans DC, Martindale RG, Kiraly LN, Jones CM. Nutrition optimization prior to surgery. Nutr Clin Pract 2014; 29:10–21.
Carvalho L, Parise ER. Evaluation of nutritional status of nonhospitalized patients with liver cirrhosis. Arq Gastroenterol 2006; 43:269–274.
Wu Y, Zhu Y, Feng Y, et al. Royal Free Hospital-Nutritional Prioritizing Tool improves the prediction of malnutrition risk outcomes in liver cirrhosis patients compared with Nutritional Risk Screening 2002. Br J Nutr 2020; 124:1293–1302.
Puri P, Dhiman RK, Taneja S, et al. Nutrition in chronic liver disease: consensus statement of the indian national association for study of the liver. J Clin Exp Hepatol 2021; 11:97–143.
Lai JC, Sonnenday CJ, Tapper EB, et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transplant 2019; 19:1896–1906.
Wang X, Feng H, Hui Y, et al. Neutrophil-to-lymphocyte ratio is associated with malnutrition risk estimated by the Royal Free Hospital-Nutritional Prioritizing Tool in hospitalized cirrhosis. JPEN J Parenter Enteral Nutr 2021; doi: 10.1002/jpen.2097. [Epub ahead of print]. (PMID: 10.1002/jpen.2097.)
Borhofen SM, Gerner C, Lehmann J, et al. The Royal Free Hospital-Nutritional Prioritizing Tool is an independent predictor of deterioration of liver function and survival in cirrhosis. Dig Dis Sci 2016; 61:1735–1743.
McFarlane M, Hammond C, Roper T, et al. Comparing assessment tools for detecting undernutrition in patients with liver cirrhosis. Clin Nutr ESPEN 2018; 23:156–161.
Tandon P, Raman M, Mourtzakis M, Merli M. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology 2017; 65:1044–1057.
Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline: clinical nutrition in liver disease. Clin Nutr 2020; 39:3533–3562.
Keller U. Nutritional laboratory markers in malnutrition. J Clin Med 2019; 8:775.
Evans DC, Corkins MR, Malone A, et al. The use of visceral proteins as nutrition markers: an ASPEN position paper. Nutr Clin Pract 2021; 36:22–28.
Odeh M, Sabo E, Srugo I, Oliven A. Serum levels of tumor necrosis factor-alpha correlate with severity of hepatic encephalopathy due to chronic liver failure. Liver Int 2004; 24:110–116.
Le Moine O, Marchant A, De Groote D, et al. Role of defective monocyte interleukin-10 release in tumor necrosis factor-alpha overproduction in alcoholics cirrhosis. Hepatology 1995; 22:1436–1439.
Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol 2012; 10:117–125.
Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007; 8:21–34.
Korinkova L, Prazienkova V, Cerna L, et al. Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides. Front Endocrinol 2020; 11:597583.
Meyer F, Bannert K, Wiese M, et al. Molecular mechanism contributing to malnutrition and sarcopenia in patients with liver cirrhosis. Int J Mol Sci 2020; 21:5357.
McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 1998; 115:947–953.
Kalaitzakis E, Bosaeus I, Ohman L, Bjornsson E. Altered postprandial glucose, insulin, leptin, and ghrelin in liver cirrhosis: correlations with energy intake and resting energy expenditure. Am J Clin Nutr 2007; 85:808–815.
Elbadri A, Esmat S, Abosaif N, et al. Study of serum ghrelin changes and its correlation with malnutrition in liver cirrhosis in Egypt. Clin Res Hepatol Gastroenterol 2011; 35:638–643.
Dornelles CT, Goldani HA, Wilasco MI, et al. Ghrelin, leptin and insulin in cirrhotic children and adolescents: relationship with cirrhosis severity and nutritional status. Regul Pept 2013; 180:26–32.
Ezquerro S, Mocha F, Fruhbeck G, et al. Ghrelin reduces TNF-alpha-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD. J Clin Endocrinol Metab 2019; 104:21–37.
Takahashi H, Kato A, Onodera K, Suzuki K. Fasting plasma ghrelin levels reflect malnutrition state in patients with liver cirrhosis. Hepatol Res 2006; 34:117–123.
Pradhan G, Samson SL, Sun Y. Ghrelin: much more than a hunger hormone. Curr Opin Clin Nutr Metab Care 2013; 16:619–624.
Li Y, Hai J, Li L, et al. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after nonalcoholic fatty liver disease development. Endocrine 2013; 43:376–386.
Moreno M, Chaves JF, Sancho-Bru P, et al. Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 2010; 51:974–985.
Conchillo M, de Knegt RJ, Payeras M, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005; 43:630–636.
Lai JC, Tandon P, Bernal W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; doi: 10.1002/hep.32049. [Epub ahead of print]. (PMID: 10.1002/hep.32049.)
Duarte-Rojo A, Ruiz-Margain A, Montano-Loza AJ, et al. Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list. Liver Transpl 2018; 24:122–139.
Sinclair M, Gow PJ, Grossmann M, Angus PW. Review article: sarcopenia in cirrhosis – aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther 2016; 43:765–777.
Hammad A, Kaido T, Uemoto S. Perioperative nutritional therapy in liver transplantation. Surg Today 2015; 45:271–283.
Le Cornu KA, McKiernan FJ, Kapadia SA, Neuberger JM. A prospective randomized study of preoperative nutritional supplementation in patients awaiting elective orthotopic liver transplantation. Transplantation 2000; 69:1364–1369.
Kaido T, Mori A, Ogura Y, et al. Pre and perioperative factors affecting infection after living donor liver transplantation. Nutrition 2012; 28:1104–1108.
Shirabe K, Yoshimatsu M, Motomura T, et al. Beneficial effects of supplementation with branched-chain amino acids on postoperative bacteremia in living donor liver transplant recipients. Liver Transpl 2011; 17:1073–1080.
Bjelakovic G, Nikolova D, Bjelakovic M, Gluud C. Vitamin D supplementation for chronic liver diseases in adults. Cochrane Database Syst Rev 2017; 11:CD011564.
Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol 2019; 54:845–859.
Chang KV, Chen JD, Wu WT, et al. Association of loss of muscle mass with mortality in liver cirrhosis without or before liver transplantation: a systematic review and meta-analysis. Medicine 2019; 98:e14373.
Cichoz-Lach H, Michalak A. A comprehensive review of bioelectrical impedance analysis and other methods in the assessment of nutritional status in patients with liver cirrhosis. Gastroenterol Res Pract 2017; 2017:6765856.
Klein CG, Malamutmann E, Latuske J, et al. Frailty as a predictive factor for survival after liver transplantation, especially for patients with MELD10.1007/s00423-021-02109-9)
Garcia PS, Cabbabe A, Kambadur R, et al. Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. Anesth Analg 2010; 111:707–709.
Ooi PH, Hager A, Mazurak VC, et al. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transpl 2019; 25:1422–1438.
Paternostro R, Lampichler K, Bardach C, et al. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. Liver Int 2019; 39:2374–2385.
Esser H, Resch T, Pamminger M, et al. Preoperative assessment of muscle mass using computerized tomography scans to predict outcomes following orthotopic liver transplantation. Transplantation 2019; 103:2506–2514.
Yao J, Zhou X, Yuan L, et al. Prognostic value of the third lumbar skeletal muscle mass index in patients with liver cirrhosis and ascites. Clin Nutr 2020; 39:1908–1913.
Li T, Xu M, Kong M, et al. Use of skeletal muscle index as a predictor of short-term mortality in patients with acute-on-chronic liver failure. Sci Rep 2021; 11:12593.
Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10:166–173. 173.e1.
Carey EJ, Lai JC, Wang CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23:625–633.
Hari A, Berzigotti A, Stabuc B, Caglevic N. Muscle psoas indices measured by ultrasound in cirrhosis - preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. Dig Liver Dis 2019; 51:1502–1507.
Sinclair M, Hoermann R, Peterson A, et al. Use of Dual X-ray Absorptiometry in men with advanced cirrhosis to predict sarcopenia-associated mortality risk. Liver Int 2019; 39:1089–1097.
Eriksen CS, Kimer N, Suetta C, Moller S. Arm lean mass determined by Dual-Energy X-ray Absorptiometry is superior to characterize skeletal muscle and predict sarcopenia-related mortality in cirrhosis. Am J Physiol Gastrointest Liver Physiol 2021; 320:G729–G740.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48:601.
Sinclair M, Chapman B, Hoermann R, et al. Handgrip strength adds more prognostic value to the Model for End-Stage Liver Disease Score than imaging-based measures of muscle mass in men with cirrhosis. Liver Transpl 2019; 25:1480–1487.
Dodds RM, Syddall HE, Cooper R, et al. Grip strength across the life course: normative data from twelve British studies. PLoS One 2014; 9:e113637.
Son SW, Song DS, Chang UI, Yang JM. Definition of sarcopenia in chronic liver disease. Life 2021; 11:349.
Dunn MA, Josbeno DA, Tevar AD, et al. Frailty as tested by gait speed is an independent risk factor for cirrhosis complications that require hospitalization. Am J Gastroenterol 2016; 111:1768–1775.
Soto R, Diaz LA, Rivas V, et al. Frailty and reduced gait speed are independently related to mortality of cirrhotic patients in long-term follow-up. Ann Hepatol 2021; 25:100327.
Salim TI, Nestlerode LC, Lucatorto EL, et al. Frailty as tested by gait speed is a risk factor for liver transplant respiratory complications. Am J Gastroenterol 2020; 115:859–866.
Deng Y, Lin L, Fan X, et al. Incorporation of frailty estimated by gait speed within MELD-Na and the predictive potential for mortality in cirrhosis. Ther Adv Chronic Dis 2020; 11:2040622320922023.
Makary MA, Segev DL, Pronovost PJ, et al. Frailty as a predictor of surgical outcomes in older patients. J Am Coll Surg 2010; 210:901–908.
Lai JC, Feng S, Terrault NA, et al. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014; 14:1870–1879.
Wang CW, Covinsky KE, Feng S, et al. Functional impairment in older liver transplantation candidates: from the functional assessment in liver transplantation study. Liver Transpl 2015; 21:1465–1470.
Essam Behiry M, Mogawer S, Yamany A, et al. Ability of the short physical performance battery frailty index to predict mortality and hospital readmission in patients with liver cirrhosis. Int J Hepatol 2019; 2019:8092865.
Xu CQ, Yao F, Mohamad Y, et al. Evaluating the associations between the liver frailty index and Karnofsky Performance Status with waitlist mortality. Transplant Direct 2021; 7:e651.
Kardashian A, Ge J, McCulloch CE, et al. Identifying an optimal Liver Frailty Index cutoff to predict waitlist mortality in liver transplant candidates. Hepatology 2021; 73:1132–1139.
معلومات مُعتمدة: K08 DK118187 United States DK NIDDK NIH HHS
المشرفين على المادة: 0 (Biomarkers)
تواريخ الأحداث: Date Created: 20210803 Date Completed: 20211028 Latest Revision: 20230917
رمز التحديث: 20230918
مُعرف محوري في PubMed: PMC8446327
DOI: 10.1097/MOT.0000000000000911
PMID: 34343156
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-7013
DOI:10.1097/MOT.0000000000000911